Advertisement

Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome

      Highlights

      • This study evaluated HDL-C and cardiovascular (CV) risk in acute coronary syndrome.
      • Lower HDL-C is associated with higher incidence of CV events.
      • Predictive ability is independent of intensive or conventional lipid-lowering therapy.
      • These trends remained after adjustment for baseline values and lipid profiles.
      • Lower BMI, diabetes mellitus, and higher hs-CRP at baseline independently predicted CV events.

      Abstract

      Background and aims

      This study aimed to elucidate whether high-density lipoprotein cholesterol (HDL-C) at 3-month follow-up for patients receiving contemporary lipid-lowering therapy after acute coronary syndrome (ACS) could predict cardiac events.

      Methods

      The HIJ-PROPER study was a multicenter, prospective, randomized trial comparing intensive lipid-lowering therapy (pitavastatin + ezetimibe) and conventional lipid-lowering therapy (pitavastatin monotherapy) after ACS. The entire cohort was divided into three groups according to tertiles of HDL-C levels at 3-month follow-up (Group 1, HDL-C ≤43 mg/dL; Group 2, HDL-C >43, <53.6 mg/dL; Group 3; HDL-C ≥53.6 mg/dL). Baseline characteristics and incidence of the primary endpoint (a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, unstable angina pectoris, or ischemia-driven revascularization) were compared among the three groups.

      Results

      The primary endpoint event occurred in 34.8%, 30.1%, and 24.6% of patients in Groups 1, 2, and 3, respectively, and its incidence was significantly higher in Group 1 than in Group 3 (hazard ratio [HR], 1.5; 95% confidence interval [CI], 1.19–1.9; p = 0.001). Irrespective of the treatment regimen, Group 1 had significantly higher rates of the primary endpoint than Group 3 (pitavastatin + ezetimibe therapy: HR, 1.6; 95% CI, 1.12–2.22; p = 0.01 and pitavastatin monotherapy: HR, 1.4; 95% CI, 1.05–1.98; p = 0.02). These trends remained even after adjustment for baseline characteristics and lipid profiles. Multivariate analysis revealed that lower body mass index, prevalence of diabetes mellitus, higher levels of high-sensitivity C reactive protein at baseline, and lower levels of HDL-C at 3-month follow-up were independent predictors of the incidence of primary endpoint.

      Conclusions

      Lower levels of HDL-C at 3-month follow-up are independently associated with higher incidence of cardiovascular events in ACS patients receiving contemporary lipid-lowering therapy.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Scandinavian Simvastatin Survival Study Group
        Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383-1389
        • Baigent C.
        • Keech A.A.
        • Kearney P.M.
        • Blackwell L.
        • Buck G.
        • et al.
        Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins.
        Lancet. 2005; 366: 1267-1278
        • Cannon C.P.
        • Blazing M.A.
        • Giugliano R.P.
        • McCagg A.
        • White J.A.
        • et al.
        Ezetimibe added to statin therapy after acute coronary syndromes.
        N. Engl. J. Med. 2015; 372: 2387-2397
        • Sabatine M.S.
        • Giugliano R.P.
        • Keech A.C.
        • Honarpour N.
        • Wiviott S.D.
        • et al.
        Evolocumab and clinical outcomes in patients with cardiovascular disease.
        N. Engl. J. Med. 2017; 376: 1713-1722
        • Boden W.E.
        High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial.
        Am. J. Cardiol. 2000; 86: 19L-22L
        • Barter P.
        • Gotto A.M.
        • LaRosa J.C.
        • Maroni J.
        • Szarek M.
        • et al.
        HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
        N. Engl. J. Med. 2007; 357: 1301-1310
        • Seo S.M.
        • Choo E.H.
        • Koh Y.S.
        • Park M.W.
        • Shin D.I.
        • et al.
        High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention.
        Heart. 2011; 97: 1943-1950
        • van de Woestijne A.P.
        • van der Graaf Y.
        • Liem A.H.
        • Cramer M.J.
        • Westerink J.
        • et al.
        Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
        J. Am. Coll. Cardiol. 2013; 62: 1834-1841
        • Ridker P.M.
        • Genest J.
        • Boekholdt S.M.
        • Libby P.
        • Gotto A.M.
        • et al.
        HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
        Lancet. 2010; 376: 333-339
        • Olsson A.G.
        • Schwartz G.G.
        • Szarek M.
        • Libby P.
        • Gotto A.M.
        • et al.
        High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
        Eur. Heart J. 2005; 26: 890-896
      1. The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction.
        Am. Heart J. 2012; 163: 705-713
        • Izuhara M.
        • Ono K.
        • Shiomi H.
        • Morimoto T.
        • Furukawa Y.
        • et al.
        High-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after percutaneous coronary intervention: a report from the CREDO-Kyoto registry cohort-2.
        Atherosclerosis. 2015; 242: 632-638
        • Silbernagel G.
        • Schöttker B.
        • Appelbaum S.
        • Scharnagl H.
        • Kleber M.E.
        • et al.
        High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality.
        Eur. Heart J. 2013; 34: 3563-3571
        • Hagiwara N.
        • Kawada-Watanabe E.
        • Koyanagi R.
        • Arashi H.
        • Yamaguchi J.
        • Nakao K.
        • et al.
        Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
        Eur. Heart J. 2017; 38: 2264-2276
        • Yamaguchi J.
        • Kawada-Watanabe E.
        • Koyanagi R.
        • Arashi H.
        • Sekiguchi H.
        • et al.
        Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: a sub-analysis of HIJ-PROPER.
        Atherosclerosis. 2018; 274: 139-145
        • Rosenson R.S.
        Myocardial injury: the acute phase response and lipoprotein metabolism.
        J. Am. Coll. Cardiol. 1993; 22: 933-940
        • Pitt B.
        • Loscalzo J.
        • Ycas J.
        • Raichlen J.S.
        Lipid levels after acute coronary syndromes.
        J. Am. Coll. Cardiol. 2008; 51: 1440-1445
        • Jahangiri A.
        • de Beer M.C.
        • Noffsinger V.
        • Tannock L.R.
        • Ramaiah C.
        • et al.
        HDL remodeling during the acute phase response.
        Arterioscler. Thromb. Vasc. Biol. 2009; 29: 261-267
        • Donahoe S.M.
        • Stewart G.C.
        • McCabe C.H.
        • Mohanavelu S.
        • Murphy S.A.
        • et al.
        Diabetes and mortality following acute coronary syndromes.
        J. Am. Med. Assoc. 2007; 298: 765-775
        • Lamelas P.
        • Schwalm J.D.
        • Quazi I.
        • Mehta S.
        • Devereaux P.J.
        • et al.
        Effect of body mass index on clinical events after acute coronary syndromes.
        Am. J. Cardiol. 2017; 120: 1453-1459
        • Kawada-Watanabe E.
        • Yamaguchi J.
        • Kanbayashi K.
        • Sekiguchi H.
        • Arashi H.
        • et al.
        Predictive value of baseline high-sensitivity C-reactive protein level and renal function for patients with acute coronary syndrome undergoing aggressive lipid-lowering therapy: a subanalysis of HIJ-PROPER.
        Am. J. Cardiol. 2018; 122: 1817-1823
        • Ray K.K.
        • Cannon C.P.
        • Cairns R.
        • Morrow D.A.
        • Ridker P.M.
        • et al.
        Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22, Arterioscler.
        Thromb. Vasc. Biol. 2009; 29: 424-430
        • Rohatgi A.
        • Khera A.
        • Berry J.D.
        • Givens E.G.
        • Ayers C.R.
        • et al.
        HDL cholesterol efflux capacity and incident cardiovascular events.
        N. Engl. J. Med. 2014; 371: 2383-2393
        • Pirillo A.
        • Catapano A.L.
        Patavastatin and HHDL: effects on plasma levels and function(s).
        Atherosclerosis Suppl. 2017; 27: e1-e9
        • Pirillo A.
        • Catapano A.L.
        Increasing high-density lipoprotein cholesterol levels for cardiovascular benefit: the end of a dream?.
        Eur. J. Prev. Cardiol. 2019; 26: 531-532
        • Nicholls S.J.
        • Andrews J.
        • Kastelein J.J.P.
        • Merkely B.
        • Nissen S.E.
        • et al.
        Effect of serial infusions of CER-001, a pre-β high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: a randomized clinical trial, JAMA.
        Cardiol. 2018; 3: 815-822
        • Tardif J.C.
        • Ballantyne C.M.
        • Barter P.
        • Dasseux J.L.
        • Fayad Z.A.
        • et al.
        Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial.
        Eur. Heart J. 2014; 35: 3277-3286
        • HPS2-Thrive Collaborative Group
        • Landray M.J.
        • Haynes R.
        • Hopewell J.C.
        • Parish S.
        • et al.
        Effects of extended-release niacin with laropiprant in high-risk patients.
        N. Engl. J. Med. 2014; 371: 203-212
        • Barter P.J.
        • Caulfield M.
        • Eriksson M.
        • Grundy S.M.
        • Kastelein J.J.
        • et al.
        Effects of torcetrapib in patients at high risk for coronary events.
        N. Engl. J. Med. 2007; 357: 2109-2122
        • Schwartz G.G.
        • Olsson A.G.
        • Abt M.
        • Ballantyne C.M.
        • Barter P.J.
        • et al.
        Effects of dalcetrapib in patients with a recent acute coronary syndrome.
        N. Engl. J. Med. 2012; 367: 2089-2099
        • Lincoff A.M.
        • Nicholls S.J.
        • Riesmeyer J.S.
        • Barter P.J.
        • Brewer H.B.
        • et al.
        Evacetrapib and cardiovascular outcomes in high-risk vascular disease.
        N. Engl. J. Med. 2017; 376: 1933-1942